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Administered by intramuscular injection, a DNA vaccine (pIRF1A-G) containing the promoter regions
upstream of the rainbow trout interferon regulatory factor 1A gene (IRF1A) driven the expression of the
infectious hematopoietic necrosis virus (IHNV) glycoprotein (G) elicited protective immune responses in
rainbow trout (Oncorhynchus mykiss). However, less laborious and cost-effective routes of DNA vaccine
delivery are required to vaccinate large numbers of susceptible farmed ﬁsh. In this study, the pIRF1A-G
vaccine was encapsulated into alginate microspheres and orally administered to rainbow trout. At 1, 3,
5, and 7 d post-vaccination, IHNV G transcripts were detected by quantitative real-time PCR in gills, spleen,
kidney and intestinal tissues of vaccinated ﬁsh. This result suggested that the encapsulation of pIRF1A-G in
alginate microparticles protected the DNA vaccine from degradation in the ﬁsh stomach and ensured
vaccine early delivery to the hindgut, vaccine passage through the intestinal mucosa and its distribution
thought internal and external organs of vaccinated ﬁsh. We also observed that the oral route required
approximately 20-fold more plasmid DNA than the injection route to induce the expression of signiﬁcant
levels of IHNV G transcripts in kidney and spleen of vaccinated ﬁsh. Despite this limitation, increased IFN-
1, TLR-7 and IgM gene expression was detected by qRT-PCR in kidney of vaccinated ﬁsh when a 10 mg dose
of the oral pIRF1A-G vaccine was administered. In contrast, signiﬁcant Mx-1, Vig-1, Vig-2, TLR-3 and TLR-8
gene expression was only detected when higher doses of pIRF1A-G (50 and 100 mg) were orally admin-
istered. The pIRF1A-G vaccine also induced the expression of several markers of the adaptive immune
response (CD4, CD8, IgM and IgT) in kidney and spleen of immunized ﬁsh in a dose-dependent manner.
When vaccinated ﬁsh were challenged by immersion with live IHNV, evidence of a doseeresponse effect
of the oral vaccine could also be observed. Although the protective effects of the oral pIRF1A-G vaccine
after a challenge with IHNV were partial, signiﬁcant differences in cumulative percent mortalities among
the orally vaccinated ﬁsh and the unvaccinated or empty-plasmid vaccinated ﬁsh were observed. Similar
levels of protection were obtained after the intramuscular administration of 5 mg of pIRF1A-G or after the
oral administration of a high dose of pIRF1A-G vaccine (100 mg); with 70 and 56 relative percent survival
values, respectively. When ﬁsh were vaccinated with alginate microspheres containing high doses of the
pIRF1A-G vaccine (50 or 100 mg), a signiﬁcant increase in the production of anti-IHNV antibodies was
detected in serum samples of the vaccinated ﬁsh compared with that in unvaccinated ﬁsh. At 10 days post
echallenge, IHNV N gene expression was nearly undetectable in kidney and spleen of orally vaccinated
ﬁsh which suggested that the vaccine effectively reduced the amount of virus in tissues of vaccinated ﬁsh
that survived the challenge. In conclusion, our results demonstrated a signiﬁcant increase in ﬁsh immune
responses and resistance to an IHNV infection after the oral administration of increasing concentrations of
a DNA vaccine against IHNV encapsulated into alginate microspheres.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).).
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Aquaculture is the fastest growing food-production sector in the
world, providing a signiﬁcant supplement to, and substitute for,
wild aquatic organisms. However, viral diseases are a primary
constraint to the growth of many aquaculture species. Infectious
hematopoietic necrosis virus (IHNV) is, in large part, responsible for
important losses in the salmonid farming industry worldwide.
Economic losses are due not only to ﬁsh mortality but also to the
quarantine, restriction of movement or destruction of IHNV-
infected ﬁsh stocks. IHNV is a non-segmented, enveloped, single-
stranded, negative-sense RNA virus belonging to the genus Nov-
irhabdovirus in the family Rhabdoviridae. The genome of the virus
(11 Kb) contains six open reading frames in the following order:
nucleocapsid (N), phosphoprotein (P), matrix protein (M), glyco-
protein (G), non-structural viral protein (NV), and polymerase
genes (L) [1,2]. Previous studies demonstrated that the IHNV G
protein is the only viral protein capable of inducing a neutralizing
antibody response to IHNV [3]. The virus was ﬁrst detected in the
Paciﬁc Northwest in the USA and is considered endemic in this area.
Despite regulatory controls to prevent its dissemination, the virus
has extended its geographical reach to European and Asiatic
countries, usually by the movement of infected eggs or ﬁsh.
Following a disease outbreak, surviving ﬁsh may be asymptomatic
carriers for life.
Preventive measures, such as effective vaccines, are critical for a
sustainable development of the aquaculture industry and have
been the focus of extensive research. In addition to reducing the
severity of disease losses, vaccines also reduce the need for anti-
biotics, leave no residues in the environment and do not induce
pathogen resistance. Although different types of vaccines against
ﬁsh viral diseases have been described, DNA vaccines have proven
particularly effective. In fact, effective DNA vaccination of a large
number of ﬁsh species against a variety of viral diseases has been
demonstrated [4,5]. The ﬁrst demonstration that the intramuscular
(i. m.) injection of a plasmid DNA encoding the IHNV G gene into
ﬁsh resulted in the transient expression of the encoded gene and in
the generation of protective immunity against an IHNV challenge
was reported by Anderson and co-workers [6]. This DNA vaccine
was designed to express the IHNV G gene under the control of the
cytomegalovirus immediate early promoter (CMVIEP). Later, a DNA
vaccine against IHNV containing the CMV promoter in place of the
CMVIEP promoter was patented in Canada and approved for
commercialization in July 2005 by the Canadian Food Inspection
Agency [7]. However, the insertion of a promoter from a human
pathogen (i.e. the CMV promoter), makes DNA vaccines containing
this promoter “unsafe” for some countries licensing agencies.
Therefore, DNA plasmid vectors containing rainbow trout speciﬁc
promoters to take the place of the human CMV promoter were
constructed [8]. One of these expression vectors, pIRF1A-G, con-
tained the IHNV G gene linked to the promoter region upstream of
the rainbow trout interferon regulatory factor 1A gene (IRF1A).
Administered by intramuscular (i. m.) injection, the effectiveness of
pIRF1A-G as IHNV DNA vaccine compared favourably with that
pCMVIEP-G in vaccine trials. Although DNA vaccines against IHNV
and the related ﬁsh rhabdovirus, viral hemorrhagic septicaemia
virus (VHSV), have been shown to stimulate the production of
speciﬁc neutralizing antibodies and to induce the expression of
non-speciﬁc IFN-inducible antiviral genes such as Mx-1 and Vig-1
in rainbow trout [9,10], the speciﬁc immune mechanisms and
correlates of protection of pIRF1A-G vaccinated ﬁsh remain to be
elucidated.
DNA vaccination by i. m. injection is very effective in inducing
ﬁsh immune responses. However, alternative routes of DNAvaccine
delivery are desirable for less stressful manipulation of the ﬁsh andfor use in small ﬁsh for which i. m. delivery is not practical or cost
effective [11]. Oral delivery of DNA vaccines is considered the most
appropriate way to immunize large numbers of small farmed ﬁsh.
Advantages of oral vaccine delivery in ﬁsh include its safe, easy
application, limited stress effects, and reduced cost, time and la-
bour. However, oral vaccine delivery has some drawbacks mainly
due to the strong physiological conditions encountered in the ﬁrst
portions of the ﬁsh gastrointestinal tract where very low pH levels
may be present [12,13]. Therefore, some antigen-encapsulation
methods have been developed to overcome vaccine degradation
in the ﬁsh stomach and to ensure the arrival of enough quantity of
plasmid vaccine to the second segment of the ﬁsh gut where uptake
occurs [14,15].
We have previously conducted several studies using an oral DNA
vaccine against infectious pancreatic necrosis virus (IPNV), a
member of the Birnaviridae family that causes widespread mor-
tality in salmonid ﬁsh. The pcDNA-VP2 vaccine, a plasmid vector
encoding the VP2 gene of IPNV, was encapsulated into alginate
microspheres for oral delivery to rainbow trout [16e18]. The
effectiveness of the pcDNA-VP2 vaccine was demonstrated when
the vaccine was orally administered by pipette directly into the
mouth of both brown trout (Salmo trutta) and rainbow trout
(Onchorrynkuss mykiss) or incorporated into food pellets [19]. After
the oral administration of the vaccine, the VP2 transgene was
expressed in several organs of vaccinated ﬁsh, induced innate and
speciﬁc immune responses, and a strong protection against an IPNV
challenge. At 30 days postechallenge with live IPNV, relative
percent survival (RPS) values of 84 in brown trout and between 67
and 83 in rainbow trout were obtained. By using an oligo micro-
array, high transcriptional levels of a group of immune-related
genes, including IFN-1, Mx-1, Mx-3, IgM and IgT, were detected in
kidney of orally vaccinated ﬁsh prior challenge suggesting that
these genes might be important for protection against IPNV [17]
Overall, these studies demonstrated the potential of using algi-
nate microspheres as an effective strategy to deliver DNA vaccines
against ﬁsh viral diseases and provided some protection correlates
that could be used to test efﬁcacy of oral DNA vaccines.
In the current study, we tested whether the pIRF1A-G vaccine
could also be effective when encapsulated in alginate microspheres
and delivered orally to rainbow trout. The protective immune re-
sponses generated by two routes of administration of the pIRF1A-G
vaccine including intramuscular injection and oral delivery in
alginate microparticles were compared. For this purpose, the
expression of IHNV G m-RNA transcripts and mRNA expression
proﬁles of several markers of the innate and adaptive immune re-
sponses including IFN-1, Mx-1, Mx-3, Vig-1, Vig-2, TLR-3, TLR-7,
TLR-8, CD4, CD8, IgM and IgT genes, were examined in kidney
and spleen of vaccinated ﬁsh. In addition, the efﬁcacy of the
pIRF1A-G vaccine (given orally or by i. m. injection) in inducing
anti-IHNV antibodies and protection against an IHNV challenge,
was evaluated. Finally, we tested whether the oral administration
of pIRF1A-G would effectively reduce viral load in vaccinated ﬁsh.2. Materials and methods
2.1. Ethics statement
All the in vivo procedures were performed in strict accordance
with the recommendations in the European Union Ethical Guide-
lines for the care of animals used for experimental and other sci-
entiﬁc purposes (2010/63/EU). All the experimental protocols were
approved by the Institutional Animal Care and Use Committee
(IACUC) of the Consejo Superior de Investigaciones Cientíﬁcas
(CSIC).
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Healthy rainbow trout specimens (3e4 ± 0.3 g mean weight)
were purchased from a spring water farm with no history of viral
diseases (Guadalajara, Spain). Fish were maintained under a 12-h-
light/12-h-dark photoperiod at 13 ± 1 C in 350-L closed ﬂow-
through water tanks (Living Stream, Frigid Units Inc., Ohio) at the
“Centro de Investigaciones Biologicas” (CSIC, Madrid, Spain). Fish
were fed daily (1.5% body weight) with a pelleted diet (Skretting,
Spain). A pool of ﬁve trout was tested to conﬁrm the absence of
IHNV or any other salmonid virus by isolation using BF2 cells [20].
Prior to any experimental procedure, ﬁsh were acclimatized to
laboratory conditions for 2 weeks, and during this period, no clin-
ical signs were observed.
2.3. Encapsulation of the pIRF1A-G DNA vaccine in alginate
microspheres
The pIRF1A-G vaccine, which contains the promoter regions of
the rainbow trout interferon regulatory 1A gene driven the
expression of the IHNV glycoprotein gene, was kindly provided by
Dr. Marta Alonso and Dr. Jo-Ann Leong. The pIRF1A-G vaccine is
covered by a patent application through Oregon State University
(WO200269840) [21]. Construction of the pIRF1A-G vaccine was
previously reported [8]. An empty plasmid lacking the IHNV G gene
(pIRF1A) was used as plasmid control in the immunization exper-
iments. Large-scale preparations of the pIRF1A-G vaccine and
pIRF1A empty plasmid were prepared from lysates of Escherichia
coli TOP10 super competent cells grown in presence of ampicillin
(Life Technologies, Alcobendas, Spain). The plasmid DNAs were
puriﬁed with the Endofree Plasmid Maxi puriﬁcation kit according
to the manufacturer's instructions (Qiagen Iberia, Spain). Puriﬁed
pIRF1A-G vaccine and pIRF1A empty plasmid (1.5 mg) were
encapsulated into alginate microspheres as previously described
[16]. Brieﬂy, 2.5 mL of 3% (w/v) sodium alginate were mixed with
1.5 mL of 1 mg mL1 of pIRF1A-G or pIRF1A and the mixture stirred
at 500 rpm during 10 min. This solution was added to an Erlen-
meyer ﬂask containing 100 mL of parafﬁn oil and 0.5 mL Span 80,
and the mixture was emulsiﬁed for 30 min at 900 rpm. Micro-
spheres were prepared by adding 2.5 mL of 0.15 M CaCl2 to the
emulsion drop by drop and stirring for 2 h at 900 rpm. Micro-
spheres were collected by centrifugation at 1000 g for 10 min, and
they were washed twice with 70% ethanol, lyophilized for 24 h and
stored at 4 C. The DNA content of the pIRF1A-G-loaded alginate
microspheres was assessed by resuspending plasmid-loaded algi-
nate microspheres in 5 mL of sodium citrate (55 mM) overnight at
room temperature. The absorbance of the supernatant was
measured at 260 nM in a NanoDrop ND-1000 Spectrophotometer
(Thermo Scientiﬁc, Wilmington, DE).
2.4. Immunization trials
In the ﬁrst laboratory trial six experimental groups of 50 ﬁsh
each (mean weight 3e4 g) were compared: (1) ﬁsh were orally
immunized with a suspension of alginate microparticles containing
10 mg of pIRF1A-G, (2) ﬁsh orally immunizedwith 10 mg of pIRF1A-G
in alginate microparticles and boosted 15 days later with the same
amount of plasmid, (3) ﬁsh orally immunized with alginate mi-
croparticles containing 25 mg of pIRF1A-G, (4) ﬁsh orally vaccinated
with 25 mg of pIRF1A-G in alginate microparticles and boosted 15
days later with the same amount of DNA, (5) ﬁsh orally immunized
with alginate microparticles containing 10 mg of pIRF1A empty
plasmid, and (6) control, unvaccinated ﬁsh. For oral immunization,
ﬁsh were anaesthetised by immersion in 50 mg mL1 of buffered
tricaine methane sulphonate (MS-222; SigmaeAldrich, Madrid,Spain) and then the corresponding amount of plasmid-loaded mi-
crospheres was introduced into the mouth of each ﬁsh with an
automatic pipette supporting a 20 mL tip end at the entrance of the
oesophagus.
In the second experimental trial, four experimental groups of
ﬁsh (n ¼ 50) were compared, including: (1) ﬁsh orally immunized
with alginate microparticles containing 100 mg of pIRF1A-G, (2) ﬁsh
injected at the base of the dorsal ﬁn with 5 mg of pIRF1A-G, (3) ﬁsh
injected with 5 mg of pIRF1A empty plasmid, and (4) control, un-
vaccinated ﬁsh.
2.5. Tissue collection, RNA extraction, cDNA synthesis and
quantiﬁcation of gene expression by a two-step quantitative
reverse-transcription PCR (qRT-PCR)
Fish were sacriﬁced via MS-222 overdose. Gills, head kidney,
spleen, and/or intestinal tissues were aseptically collected from
vaccinated and unvaccinated trout and individually stored in 1 mL
of TRIzol LS Reagent (Invitrogen, Spain) at e 70 C until RNA
isolation. Tissue samples were homogenized using the Tissue Lyser
Cell Disruptor (Qiagen S. A., Madrid, Spain) 5 min at 50 Hz with
2 mm glass beads. Total RNA was isolated from different tissues by
using the TRIzol LS Reagent according to the manufacturer's in-
structions. RNAs were treated with DNase I-RNase Free (Fermentas,
Spain) to remove genomic DNA that might interfere with the PCRs.
The purity and the yield of the RNA samples were analysed in a
NanoDrop™ 1000 spectrophotometer. RNA quality was determined
bymeasuring the 260/280-nm absorbance ratio, and ratios of 1.8 or
higher were considered acceptable for puriﬁed RNA. Total RNA
(5 mg) was then reverse transcribed to c-DNA using the Super
Script™ III cDNA synthesis kit and oligo-(dT) primer (25 pmol/mL)
according to the manufacturer's instructions (Life Technologies).
The cDNA was diluted 1:4 in DEPC treated water and 2 mL of the
diluted cDNA was used in each real-time qPCR reaction. Real-time
qPCR reactions for the ampliﬁcation of each target gene were per-
formed in a 25 mL ﬁnal volume containing 12.5 mL of 2  Quantimix
Easy SYBR Green (Biotools Labs, Madrid, Spain), 0.3 mM of forward
and reverse primers, 8.5 mL of ultrapure water and 2 mL of diluted
cDNA. Real-time qPCR ampliﬁcations of c-DNA were accomplished
in an iQ5 iCycler Real-Time PCR Detection System (Bio-Rad Labo-
ratories, Madrid, Spain) under the following conditions: 1 cycle of
95 C for 10 min, followed by 40 cycles of denaturation at 95 C for
30 s, annealing at 60 C for 1 min, and a dissociation cycle (1 min at
95 C and 1 min at 60 C). After the run, the melting curve of each
amplicon was analysed to determine the speciﬁcity of the ampli-
ﬁcation. Table 1 shows the list of the ampliﬁed trout genes, their
accession numbers and corresponding primer sequences. Since the
trout Elongation Factor 1a (EF-1a) is constitutively expressed, it
was used as the endogenous gene control to normalize the
expression of each target gene in each RNA sample. PCR ampliﬁ-
cations of the IHNV G gene were carried out using TaqMan probes
and speciﬁc primers as previously described [16]. The rainbow
trout b-actin gene was used as the endogenous control gene for the
normalization of the IHNV G gene expression. Results were ana-
lysed using the iQ5 optical system software version 2.0 (Bio-Rad)
and expressed as 2DCT where DCT is determined by subtracting the
EF-1a (or actin) threshold cycle (CT) from the target CT value [22].
Negative controls with no template where included in all experi-
ments. All the PCR ampliﬁcations were performed by duplicate, and
each experiment was repeated twice to conﬁrm the results.
2.6. IHNV experimental challenge by immersion
At 30 days post-vaccination (p.v.), duplicate sets of 15 ﬁsh
(averageweight of 4 g) from each treatment groupwere challenged
Table 1
Genes and primer sequences used in the qRT-PCR assays.
Code Name Abbreviation Primer code/sequence (50-3)
NM_001124531 Type I Interferon IFN-1 F/AAAACTGTTTGATGGGAATATGAAA
R/CGTTTCAGTCTCCTCTCAGGTT
NM_001171901 Interferon-induced protein Mx1 Mx-1 F/AGCTCAAACGCCTGATGAAG
R/ACCCCACTGAAACACACCTG
U47946.1 Interferon-induced protein Mx3 Mx-3 F/AGCTCAAACGCCTGATGAAG
R/TGAATATGTCTGTTATCCTCCCAAA
AF076620.1 Viperin 1 Vig-1 F/ACGACCTCCAGCTCCCAAGT
R/GTCCAGGTGGCTCTTCCTGC
AF290477.1 Viperin 2 Vig-2 F/CCACCCACGTCATATCAGGG
R/AACGCAGACGCTTGTTGGC
ABE69177 Toll-like receptor 3-like protein TLR-3 F/AGCCCTTTGCTGCCTTACAGAG
R/GTCTTCAGGTCATTTTTGGACACG
GQ422119 Toll-like receptor 7 TLR-7 F/TACAGCTTGGTAACATGACTCTCC
R/CAACTCTCTGAGACTTGTCGGTAA
GQ422120 Toll-like receptor 8a2 TL8a2 F/CAGCATTGAACGGGACAGAG
R/CGTTGTCATAGGCCAGGTCA
AY973030.1 T-cell surface glycoprotein CD4 CD4 F/CCTGCTCATCCACAGCCTAT
R/CTTCTCCTGGCTGTCTGACC
NM_001124263 T-cell surface glycoprotein CD8 alpha precursor CD8 F/AGTCGTGCAAAGTGGGAAAG
R/GGTTGCAATGGCATACAGTC
X65263.1 Membrane bound Immunoglobulin M IgM F/ACCTTAACCAGCCGAAAGGG
R/TGTCCCATTGCTCCAGTCC
AY870265 Immonoglobulon Tau heavy chain IgT F/AGCACCAGGGTGAAACCA
R/GCGGTGGGTTCAGAGTCA
L40883 Nucleocapsid protein N F/TGTGCATGAAGTCAGTGGTGG
R/CCTGCTCATCATGACACCGTA
AF498320 Elongation factor EF1 alpha EF-1a F/GATCCAGAAGGAGGTCACCA
R/TTACGTTCGACCTTCCATCC
Y18854.1 Glycoprotein protein G gene F/GCGCACGCCGAGATAATATCAA
R/TCCCGTGATAGATGGAGCCTTT
P/CGATCTCCACATCCCGGAATAAATGACGTCT
AJ438158 Actin beta b-actin F/GGCCGTGTTGTCCCTGTAC
R/CCGGAGTCCATGACGATACC
P/CCTCTGGCCGTACCACC
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3 h at 14 ± 1 C with aeration. Dead ﬁsh were collected daily for 30
days postechallenge. Moribund ﬁsh displayed classical signs of
IHNV infection such as distended abdomens, darkened body
coloration and vertical drifting. Approximately, 10% of the dead ﬁsh
were assessed by PCR ampliﬁcation of the IHNV N gene to conﬁrm
that they died as a result of an IHNV infection. Vaccine efﬁcacy was
assessed by comparing the ﬁnal cumulative percent mortality
(CPM) among vaccinated and unvaccinated ﬁsh. The relative
percent survival (RPS) value of each experimental group was
calculated according to the following formula: RPS ¼ [1 e (CPM
vaccinated ﬁsh/CPM unvaccinated ﬁsh)]  100 [23].2.7. Indirect enzyme-linked immunosorbent assay (ELISA) for the
detection of anti-IHNV serum antibodies
At 15, 30 and 45 days p. v., rainbow trout were sacriﬁced by
immersion in an overdose solution of MS-222 (200 mg mL1), and
blood was collected from the caudal vein of vaccinated and un-
vaccinated ﬁsh using a 25-gauge needle (Becton, Dickinson and
Company, Sparks, MD, US). Blood samples were allowed to clot at
room temperature for 2 h, stored at 4 C overnight, and then
centrifuged at 500 g for 10 min. Serum samples were collected and
stored at 20 C until they were analysed by ELISA. Brieﬂy, 96-well
microtiter plates (Greiner Bio-one, Frickenhausen, Germany) were
coatedwith 100 mL of IHNV previously propagated in BF-2 cells; the
cell culture medium was used as negative antigen control. After
incubation for 18 h at 4 C, unbound virus was removed bywashing
each well ﬁve times with 200 mL of PBS with 0.05% Tween 20 (PBS-
T). The plates were then blocked for 2 h at 22 C with blockingsolution consisting of 5% skimmed milk in PBS. The plates were
washed three times with PBS-T, and 100 mL of each ﬁsh serum
sample serially diluted in PBS with 1% bovine serum albumin (BSA)
was added in triplicate. After 3 h of incubation at 22 C, the plates
were washed three times with 200 mL of PBS-T. Each well was then
inoculated with 100 mL of the anti-rainbow trout IgM monoclonal
antibody (Aquatic Diagnostics Ltd, Stirling, Scotland) and incubated
at room temperature for 1 h. Unbound antibody was removed after
three washes with 200 mL of PBS-T. Each well was then inoculated
with 100 mL of horseradish peroxidase-conjugated goat anti-mouse
IgM polyclonal antibody (Dako, Glostrup, Denmark), diluted 1:1000
in PBS with 1% BSA and incubated at 22 C for 1 h. Unbound con-
jugate was removed after 5 washes with 200 mL of PBS-T, and then
antibody binding was visualized by adding 100 mL of 3, 30, 5, 50-
tetramethylbenzidine dihydrochloride (TMB) to each well. The
plates were incubated for 10 min at 22 C in the dark, and the re-
actions were stopped by adding 50 mL of H2O2 per well. The optical
density (OD) in each well was measured at 450 nm by an ELISA
microplate reader (Model M680, Bio-Rad, Spain). The speciﬁc
antibody titre of each sample was expressed as mean OD values
(±SE) after subtracting OD values from the unvaccinated ﬁsh.2.8. Statistical analysis
Differences in CPMs between vaccinated and control ﬁsh groups
were statistically analysed, using a Fisher's exact test (GraphPad
Prism version 4.03, GraphPad Software, San Diego, CA). Differences
in gene expression between experimental groups were analysed
using factorial ANOVAs with the TukeyeKramer adjustment for
multiple comparisons (IBM SPSS Statistics 15; Chicago, IL, US). A
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statistical signiﬁcance of the gene expression levels obtained from
all the immunized experimental groups. In all analyses, differences
between groups were considered statistically signiﬁcant when the
correlation value P was <0.05.
3. Results
3.1. IHNV G transcripts were expressed in several ﬁsh organs after
oral vaccination with pIRF1A-G encapsulated in alginate
microspheres
To verify whether alginate microspheres protected the pIRF1A-
G vaccine from stomach degradation, IHNV G expression was
examined in gills, kidney, spleen, and intestinal tissues of rainbow
trout vaccinated with a 10 mg dose of the vaccine. At 1, 3, 7 and 15
days p. v., low but appreciable levels of transgene expression were
observed in all the examined organs (Fig. 1). When the G gene
expression in the four examined organs was compared, the lowest
expression levels were detected in kidney of vaccinated ﬁsh at the
four assessed time points. In contrast, the highest IHNV G gene
expression levels were recorded in intestinal tissues of the vacci-
nated ﬁsh at 1 and 3 days p. v. These ﬁndings suggested that the
encapsulation of pIRF1A-G vaccine in alginate microspheres
ensured the early delivery of the vaccine to the hindgut, its passage
through the intestinal mucosa and its distribution thought internal
and external organs of vaccinated ﬁsh.
3.2. Expression of IHNV-G, TLRs, IFN-1, and IFN-inducible genes in
response to the oral or intramuscular administration of the pIRF1A-
G vaccine
We compared the transcriptional proﬁles of several host im-
mune markers after the oral pIRF1A-G immunization with those
induced after pIRF1A-G injection. Some genes previously found
highly expressed (>2-fold) in oral pcDNA-VP2 vaccinated trout and/
or induced after IPNV-infection were selected for the currentFig. 1. IHNV G gene expression in trout tissues after oral immunization with pIRF1A-G-
loaded alginate microparticles. Rainbow trout were immunized with 10 mg of alginate-
encapsulated pIRF1A-G vaccine. IHNV G expression was analysed by qRT-PCR in gills,
kidney, spleen and intestinal tissues collected from four vaccinated rainbow trout 1, 3,
7 and 15 days after immunization. Results were analysed using the iQ5 optical system
software version 2.0 (Bio-Rad) and expressed as the mean 2DCT where DCT is the Ct
(target gene) e Ct (EF-1a). In the ﬁgure, IHNV G gene expression is presented as a
percentage of the initial amount of vaccine orally given (10 mg).analysis [18]. The selected genes belonged to (i) the innate immune
response such as IFN-1 [24,25], Mx-1 [26], Mx-3 [27], Vig-1 [28],
Vig-2 [29], TLR-3 [30], TLR-7, TLR-8 [31]; and (ii) the adaptive im-
mune response such as IgM [32,33], IgT [34], CD4 and CD8 [35].
Table 1 shows the corresponding primer sequences designed for
the qRT-PCR analysis of those genes. Because head kidney and
spleen are both target organs of IHNVmultiplication and two of the
most important trout immune-responsive organs, they were both
selected as target organs for transcriptional analysis. In order to
determine whether increasing doses of the oral pIRF1A-G vaccine
would signiﬁcantly increase the expression of the selected immune
markers, groups of rainbow trout were immunized with alginate
microparticles containing 10, 25 or 100 mg of pIRF1A-G-loaded
alginate microparticles. Fish intramuscularly injected with 5 mg of
pIR1A-G and unvaccinated ﬁsh were used as positive and negative
controls, respectively. At 3, 7 and 15 days p. v., kidney and spleen
were collected from four ﬁsh of each group and analysed for gene
expression by qRT-PCR. The transcription levels of the rainbow
trout Mx-1, Mx-3, Vig 1, Vig 2, TLR-3, TLR-7 and TLR-8 genes in
kidney and spleen of vaccinated and unvaccinated animals were
normalised to the expression of the endogenous control, Elongation
factor 1a (EF-1a), and the corresponding results are shown in Figs. 2
and 3 according to the assessed organ. The expression of the IHNV
G gene was also included in the analysis as a vaccine marker. As
expected, our results demonstrated that the expression of the IHNV
G transgene in kidney and spleen of vaccinated animals increased
with increasing concentrations of the oral vaccine. Since we pre-
viously observed that empty plasmids only induced marginal in-
creases in host gene expression and our goal was to compare
protective immune responses induced by two routes of vaccine
delivery, a common unvaccinated control group was used to
determine the statistical signiﬁcance of the gene expression levels
obtained from all the immunized experimental groups.
Of the three assessed doses of oral vaccine, only the 100 mg dose
induced signiﬁcant levels of IHNV G transcripts in kidney and
spleen of vaccinated ﬁsh. Furthermore, higher levels of IHNV G
expression were detected in kidney of ﬁsh orally vaccinated with
100 mg of pIRF1A-G vaccine than in injected ﬁsh at all the assessed
time points. Only at day 7 p. v., higher levels of IHNV G expression
were detected in spleen of ﬁsh orally vaccinated with the 100 mg
dose when compared with the injected ﬁsh.
Gene expression analysis in kidney of oral and intramuscular
vaccinated ﬁsh showed signiﬁcant increases in the expression of
most of the examined host genes (Fig. 2). After oral vaccination
increased IFN-1 and TLR-7 gene expression was observed in kidney
of vaccinated ﬁsh even when the lowest dose of the vaccine was
administered. Statistical analysis of the date indicated that the Mx-
1, Vig-2, and TLR-3 genes were highly expressed in ﬁsh orally
vaccinated with a vaccine dose25 mg. A signiﬁcant increase inVig-
1, Mx-3 and TLR-8 gene expression was only detected in kidneys of
the ﬁsh orally vaccinated with the highest dose of the DNA vaccine
(100 mg). Remarkably, a signiﬁcant induction of IFN-1 gene
expression was detected after immunization with the three
assessed doses of oral DNA vaccine and at 3, 7 and 15 days p.v.
Whenwe compared the two routes of vaccine delivery, we detected
similar IFN-1 gene expression in kidney of injected ﬁsh and in the
ﬁsh groups vaccinated with the oral DNA vaccine. However, sig-
niﬁcant differences in the expression of the Mx-1 at day 3 p. v., Mx-
3 at day 7 p. v. and TLR-7 and TLR-8 genes at days 7 and 15 p. v. were
observed depending on the vaccine delivery method. Interestingly,
the administration of 100 mg of the oral vaccine induced high levels
of TLR-7 and TLR-8 gene expression over time, which at 7 and 15
days p. v. were higher than the levels induced by the intramuscular
injection of the DNA vaccine, while no differences were recorded in
the ﬁrst 3 days p. v. As seen in Fig. 2, the increase in TLR-7 and TLR-8
Fig. 2. IHNV-G, TLRs, IFN-1, and IFN-stimulated gene expression in kidney after oral immunization of rainbow trout with increasing concentrations of pIRF1A-G-loaded alginate
microparticles. Rainbow trout were immunized with 10, 25 and 100 mg of alginate-encapsulated pIRF1A-G vaccine. IFN-1, Mx-1, Mx-3, Vig-1, Vig-2, TLR-3, TLR-7, and TLR-8 gene
expression was evaluated by qRT-PCR in kidney of four vaccinated ﬁsh at 1, 3, 7 and 15 d p. v. The analysis of the IHNV G expression was also included as a vaccine marker. Fish
intramuscularly injected with 5 mg of pIR1A-G and unvaccinated ﬁsh were used as positive and negative controls, respectively. qRT-PCR results were analysed using the iQ5 optical
system software version 2.0 (Bio-Rad) and expressed as 2DCT where DCT is the mean Ct (target gene) e Ct (EF-1a). Asterisks indicate signiﬁcant differences of expression (P  0.05);
black points indicate signiﬁcant differences between oral and intramuscular vaccinated ﬁsh.
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the vaccine was an initial response which was then quickly
suppressed.
The transcription levels of the rainbow trout Mx-1, Mx-3, Vig 1,
Vig 2, TLR-3, TLR-7 and TLR-8 genes were also examined in the
spleens of the ﬁsh orally vaccinated with increasing concentrations
of the oral pIRF1A-G vaccine. The corresponding results are pre-
sented in Fig. 3. As expected, a dose-dependent effect of the vaccine
on gene expressionwas evident. When gene expression in spleen of
ﬁsh injected with 5 mg of pIRF1A-G and orally vaccinated with
100 mg of the vaccine was compared, similar levels of IFN-1, Vig-2
and Mx-1 expression were detected at three assessed time points.
Remarkably, the administration of 100 mg of the oral vaccine
induced higher levels of TLR-3, TLR-7 and TLR-8 gene expression in
spleen of the vaccinated animals at day 7 p. v. than did the intra-
muscular injection of the DNAvaccine. At 15 days p. v., only the TLR-
8 gene remained highly expressed in spleen of orally vaccinated
ﬁsh when compared with the levels of expression of this gene in i.
m. injected ﬁsh.3.3. CD4, CD8, IgM and IgT gene expression in response to the oral
or intramuscular administration of the pIRF1A-G vaccine
Cellular-speciﬁc immune responses induced after the oral or
intramuscular administration of pIRF1A-G vaccine were evaluated
at 15 days p. v. in spleen and kidney of vaccinated ﬁsh by qRT-PCR.
Four markers of the cellular immune response including the
rainbow trout CD4, CD8, IgM and IgT genes were selected for gene
expression analysis. As seen in Fig. 4, CD4 and CD8 expression levels
were signiﬁcantly higher in kidney of orally vaccinated ﬁsh (100 mg
dose) than in i. m. injected ﬁsh. A lower dose of the oral vaccine
(25 mg) was also able to induce signiﬁcant levels of CD4 gene
expression in spleen of vaccinated ﬁsh. CD8 expression levels were
lower than those of CD4 regardless of the treatment and were
higher in the ﬁsh vaccinated with 100 mg of pIRF1A-G than in any
other experimental group. Interestingly, the i. m. injection of the
vaccine did not induce signiﬁcant levels of CD8 gene expression in
kidney and spleen of vaccinated ﬁsh. The transcription levels of IgM
and IgT genes at 15 days p. v. were also analysed by qRT-PCR in
Fig. 3. IHNV-G, TLRs, IFN-1, and IFN-stimulated gene expression in trout spleen after immunization with increasing concentrations of pIRF1A-G-loaded alginate microparticles.
Rainbow trout were immunized with 10, 25 and 100 mg of pIRF1A-G-loaded alginate microparticles. IFN-1, Mx-1, Mx-3, Vig-1, Vig-2, TLR-3, TLR-7, and TLR-8 gene expression was
evaluated at 1, 3, 7 and 15 d p. v. by qRT-PCR in spleen of four vaccinated ﬁsh. The analysis of the expression of the IHNV G gene was also included as a vaccine marker. Fish
intramuscularly injected with 5 mg of pIR1A-G and unvaccinated ﬁsh were used as positive and negative controls, respectively. qRT-PCR results were analysed using the iQ5 optical
system software version 2.0 (Bio-Rad) and expressed as 2DCT where DCT is the mean Ct (target gene) e Ct (EF-1a). Asterisks indicate signiﬁcant differences (P  0.05) of expression;
black points indicate signiﬁcant differences between oral and intramuscular vaccinated ﬁsh.
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(Fig. 4). No signiﬁcant differences in IgM gene expression were
observed between the injected and orally vaccinated ﬁsh regardless
of the assessed tissue. Administration of the vaccine orally or by
injection induced signiﬁcant IgM expression in kidney tissues. Even
at the lowest dose of the oral vaccine, a signiﬁcant increase in IgM
expression was detected in the kidney of vaccinated animals. In
contrast, only the highest dose of the oral vaccine induced signiﬁ-
cant IgT expression in kidney and spleen of vaccinated animals.
Remarkably, no signiﬁcant production of IgT transcripts were
detected in kidney of the i. m. injected ﬁsh.
3.4. Alginate-encapsulated pIRF1A-G vaccine protected orally
vaccinated ﬁsh against a lethal challenge with IHNV
In the ﬁrst experimental trial, increasing concentration of
alginate-encapsulated pIRF1A-G vaccine were orally administered
to rainbow trout fry and evaluated for their efﬁcacy in inducing a
protective immune response against an IHNV challenge. Groups of
50 rainbow trout were orally immunized with alginate micropar-
ticles containing (1) 10 mg of pIRF1A-G, (2) 10 mg of pIRF1A-G and
boosted 15 days later with the same amount of plasmid, (3) 25 mg ofpIRF1A-G, and (4) 25 mg of pIRF1A-G and boosted 15 days later with
the same amount of DNA. Fish orally immunized with alginate
microparticles containing 10 mg of empty-plasmid and unvacci-
nated ﬁsh were used as negative controls. At 30 days p. v., two
subgroups of 15 ﬁsh form each group were challenged by immer-
sionwith 105 TCID50 mL1 of IHNV.Mortality was recorded daily for
30 days. The effects of increasing concentrations of the oral DNA
vaccine on CPM are shown in Fig. 5A. In general, our results showed
that alginate-encapsulated pIRF1A-G vaccinated ﬁsh exhibited less
mortality than the empty-plasmid vaccinated or unvaccinated ﬁsh.
At 30 days postechallenge, immunizationwith 10, 20, 25 and 50 mg
of the oral DNA vaccine resulted in CMPs of 78, 70, 70, and 54%,
respectively. In contrast, the control ﬁsh that received orally the
empty-plasmid and the unvaccinated animals exhibited CMPs of 90
and 100%, respectively. Although the protective effects of the oral
pIRF1A-G vaccine after challenge with live IHNV were partial, sta-
tistically signiﬁcant differences in mortalities between the ﬁsh
orally vaccinated with 10, 20, 25 and 50 mg of the DNA vaccine and
the empty-plasmid vaccinated or unvaccinated ﬁsh were observed;
RPSs of 21, 30, 30 and 45, respectively. No signiﬁcant differences in
mortalities were observed between the empty-plasmid vaccinated
ﬁsh and the unvaccinated ﬁsh (P ¼ 0.0015). CMP in the challenged
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group, resulting in an RPS of 45.
In the second experimental trial, the effect of a higher dose of
the oral pIRF1A-G vaccine (100 mg) on ﬁsh CPMwas evaluated. Fish
injected with 5 mg of pIRF1A-G or pIRF1A empty plasmid were used
as positive and negative control groups, respectively. Unvaccinated
ﬁshwere used as the negative control group for RPS calculations. As
shown in Fig. 5B, immunization with 100 mg of the oral pIRF1A-G
vaccine resulted in a CPM of 43.75 while the CPM in the injected
group was 30% (P ¼ 0.0566). In contrast, 100% and 90% of the un-
vaccinated and empty-plasmid vaccinated ﬁsh succumbed to virus
challenge, respectively. Therefore, both injected ﬁsh and orally
vaccinated ﬁsh were signiﬁcantly protected against the challenge
with IHNV when compared with unvaccinated or empty-plasmid
injected ﬁsh (P  0.001). RPS values were calculated for each
challenged experimental group and are shown in Fig. 5B. In sum-
mary, our data indicated that the oral administration of a 100 mg
dose of pIRF1A-G induced signiﬁcant protection similar to that
obtained when ﬁsh were vaccinated by i. m. injection with 5 mg of
the DNA vaccine; 56 and 70 RPS, respectively.
3.5. Assessment of IHNV viral load in vaccinated and unvaccinated
trout after challenge with live IHNV
To determine whether the oral administration of pIRF1A-G
(10 mg dose) would reduce viral load in vaccinated ﬁsh, the tran-
scriptional levels of the IHNVnucleoprotein genewere quantiﬁed by
qRT-PCR in spleen, kidney, gills and intestinal tissues of vaccinated
and unvaccinated ﬁsh that survived the IHNV challenge (Fig. 6). AtFig. 4. CD4, CD8, IgM and IgT gene expression in trout kidneys and spleens after oral imm
with 10, 25 and 100 mg of pIRF1A-G-loaded alginate microparticles. Fish intramuscularly in
controls, respectively. Gene expression was evaluated at 15 d p. v. as described in the legend
vaccinated and unvaccinated ﬁsh or between oral and intramuscular vaccinated ﬁsh, respe10 days postechallenge, the levels of IHNV N gene expression in
vaccinated ﬁsh were lower than that quantiﬁed in unvaccinated ﬁsh
regardless of the assessed organ. Furthermore, N transcript
expression was highest in spleen of unvaccinated ﬁsh than in other
tested organs. Conversely, N gene expression was nearly undetect-
able in kidney and spleen of vaccinated ﬁsh which suggested that
the oral vaccine signiﬁcantly reduced the amount of virus in ﬁsh
internal organs. As a consequence, the risk that vaccinated carriers
will spread the disease is much lower than unvaccinated carriers.
3.6. IFN-1, Mx-1, Mx-3, Vig-1 and Vig-3 gene expression in
vaccinated and unvaccinated trout after challenge with live IHNV
Ten days after challenge with IHNV, the levels of IFN-1, Mx-1,
Mx-3, Vig-1 and Vig-3 gene expression were examined in kidney
and spleen of three orally vaccinated ﬁsh (10 mg dose of pIRF1A-G)
and the results are presented in Fig. 6B and C, respectively.
Although no signiﬁcant differences in the expression of Mx-1, Mx-
3, Vig-1 and Vig-3 genes in kidney of vaccinated and unvaccinated
ﬁsh was evident a signiﬁcant increase in IFN-1 gene expressionwas
observed 10 days after challenge in spleen of vaccinated ﬁsh when
compared with unvaccinated ﬁsh.
3.7. Alginate-encapsulated pIRF1A-G vaccine induced the
production of anti-IHNV antibodies in the serum of the vaccinated
ﬁsh
At 15, 30 and 45 days p. v. and before challengewith IHNV, blood
samples were collected from the caudal vein of orally vaccinatedunized with pIRF1A-G-loaded alginate microparticles. Rainbow trout were immunized
jected with 5 mg of pIR1A-G and unvaccinated ﬁsh were used as positive and negative
of Fig. 3. Asterisks and black points indicate signiﬁcant differences (P  0.05) between
ctively.
Fig. 5. A- Cumulative percent mortalities (CPM) of rainbow trout after the oral administration of the alginate-encapsulated pIRF1A-G vaccine and subsequent challenge with IHNV.
A- Groups of 50 rainbow trout were orally immunized with alginate microparticles containing 10 mg of pIRF1A-G, 10 mg of pIRF1A-G and boosted 15 days later with the same amount
of plasmid, 25 mg of pIRF1A-G, and 25 mg of pIRF1A-G and boosted 15 days later with the same amount of DNA. Fish orally immunized with alginate microparticles containing 10 mg
of empty-plasmid and unvaccinated ﬁsh were used as negative controls. At 30 days p. v., two subgroups of 15 ﬁsh form each group were challenged by immersion with IHNV at a
concentration of 105 TCID50 mL1. Mortality was recorded daily for 30 days. B- In a second trial, groups of 50 trout each were immunised by i. m. injection with 5 mg of pIRF1A-G or
orally with 100 mg of pIRF1A-G-loaded alginate microparticles. As controls, groups of ﬁsh were injected with 5 mg of the empty-plasmid or remained unvaccinated. After 30 days, the
ﬁsh were challenged with IHNV (105 TCID50 mL1) by immersion and monitored for the next 30 days. CPM of each treatment group was recorded, and the relative percent survival
(RPS) was calculated using the formula RPS ¼ [1 e (% mortality vaccinated ﬁsh/% mortality unvaccinated ﬁsh) e 100]).
Fig. 6. Viral load (A) and cytokine gene expression (B and C) was determined in tissues of trout orally vaccinated and then challenged with IHNV. Fish orally vaccinated with 10 mg of
alginate-encapsulated pIRF1A-G and unvaccinated ﬁsh were included in this assay. At 10 days postechallenge, three trout from each group were sacriﬁced and the RNA was
individually extracted. A. The levels of expression of the IHNV N gene in spleen, kidney, intestine, and gills of unvaccinated and orally vaccinated ﬁsh were determined using qRT-
PCR. B and C. IFN-1, Mx-1, Mx-3, Vig-1, and Vig-3 were assessed by qRT-PCR in kidney (B) and spleen (C) of unvaccinated and orally vaccinated ﬁsh. All qRT-PCR results were
analysed using the iQ5 optical system software version 2.0 (Bio-Rad) and expressed as 2DCT where DCT is the mean Ct (target gene) e Ct (EF-1a). Values with asterisks are
statistically different (P  0.05).
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with 5 mg of pIRF1A-G (n ¼ 10). The corresponding serum samples
were tested for anti-IHNV antibodies by ELISA. As seen in Fig. 7,
anti-IHNV antibodies were produced in response to the oral and
intramuscular administration of pIRF1A-G. Remarkably, no signiﬁ-
cant differences in antibody productionwere detected between the
three groups of vaccinated ﬁsh at the three assessed p. v. time
points.4. Discussion
A DNA vaccine (pIRF1A-G) containing the promoter regions
upstream of the rainbow trout IRF1A gene driven the expression of
the IHNV glycoprotein previously conferred a high level of protec-
tion against an IHNV challenge when administered by intramus-
cular injection [8]. Although effective, injection route is labour
intensive and only practiced for high-value species. Alternatively,
the current study represents the ﬁrst description of successful oral
immunization of rainbow trout against a ﬁsh Novirhabdovirus.
Following oral immunization with 10 mg of pIRF1A-G-loaded
alginate microparticles, we were able to detect IHNV G transgene
expression by qRT-PCR in gills, spleen, kidney, and intestinal tissues
of vaccinated ﬁsh. The highest IHNV G gene expression levels were
recorded in intestinal tissues early after the oral administration of
pIRF1A-G (1 and 3 d p. v.), suggesting that alginate microparticles
effectively protected the DNA vaccine avoiding its degradation in
the ﬁsh stomach at least to some degree. From our results, we can
also infer that the oral pIRF1A-G vaccine crossed the intestinal
epithelium by a still unknown mechanism, was transported into
the blood and was able to reach several internal and external or-
gans of the ﬁsh. Consequently, IHNV-G transcripts could be detec-
ted in spleen, kidney and gills of vaccinated ﬁsh at 1, 3, 7 and 15
days after vaccination. When G gene expression in the four exam-
ined organs was compared, the lowest expression levels were
detected in kidney of vaccinated ﬁsh at the four assessed timeFig. 7. Alginate-encapsulated pIRF1A-G vaccine induced the production of anti-IHNV
antibodies in serum of vaccinated ﬁsh. At 15, 30 and 45 days p. v. and before chal-
lenge with IHNV, blood samples were collected from the caudal vein of ﬁsh orally
vaccinated with 50 and 100 mg of pIRF1A-G, and from ﬁsh injected with 5 mg of pIRF1A-
G. The corresponding serum samples were tested for anti-IHNV antibodies by ELISA.
The bars represent the mean antibody levels for 10 ﬁsh tested at each time point. i.m.:
intramuscularly delivered vaccine; zero: unvaccinated ﬁsh.points. As we previously suggested, the ﬁsh head kidney might be
acting as a scavenger tissue, clearing the blood from circulating
plasmid DNA [18].
As expected, our results demonstrated that the expression of
IHNV G transcripts in kidney and spleen of vaccinated trout
increased when increasing concentrations of pIRF1A-G loaded
alginate microparticles. Although alginate microparticles are very
resistant to acidic pH, which impedes degradation of the vaccine in
the stomach of the ﬁsh (pH 2e4) and favours its release in the
foregut and hindgut (pH 7.0 and 8.3, respectively), our results
indicated that the oral route required approximately 20-fold more
plasmid DNA than the injection route to achieve signiﬁcant levels of
IHNV G expression in ﬁsh internal organs. After the vaccine pass
through the intestinal epithelium, however, similar IFN-1 and Vig 2
gene expression was detected in kidney and spleen of vaccinated
ﬁsh at 3, 7 and 15 days p. v., regardless of the administration route.
Moreover, a low dose of the oral vaccine (10 mg) was able to stim-
ulate the expression of IFN-1, TLR-7 and IgM genes in kidney of
orally vaccinated ﬁsh. In addition, the oral administration of 10 mg
of pIRF1A-G vaccine resulted in a signiﬁcant induction of Mx-1, Vig-
1, Vig-2 and TL-7 gene expression at 3 d p. v. in spleen of vaccinated
trout. Remarkably, IFN-1 gene expression was signiﬁcantly induced
by the three tested doses of the oral DNA vaccine (10, 25 and
100 mg) in spleen and kidney of vaccinated ﬁsh. In contrast, sig-
niﬁcant Mx-1, Vig-1, Vig-2, TLR-3 and TLR-8 gene expression was
only detected when high doses of pIRF1A-G vaccine were orally
administered (50 and 100 mg).
TLRs are transmembrane proteins that recognise conserved
pathogen structures. In ﬁsh, several studies have reported that TLRs
expression is regulated by viral infections [31,36]. Our results sug-
gested that TLR-3, TLR-7 and TLR-8 expression was affected by the
oral and intramuscular administration of pIRF1A-G vaccine.
Therefore, these TLRs might be acting as important mediators of
IHNV DNA vaccines in rainbow trout. Remarkably, the administra-
tion of 100 mg of the oral vaccine induced higher levels of TLR-3,
TLR-7 and TLR-8 gene expression in spleen of the vaccinated ani-
mals at day 7 p. v. than did the intramuscular injection of the DNA
vaccine. It remains to be elucidated whether oral IHNV DNA
vaccination with pIRF1A-G-loaded alginate microparticles mimics
several other transcriptional responses occurring after infection
with IHNV. Previously, we demonstrated that the oral-alginate
VP2-vaccination immunizes trout against IPNV in a similar way as
IPNV infection does [18].
Although similar levels of IFN-1 and Vig-2 gene expressionwere
detected in kidney and spleen of vaccinated ﬁsh regardless of the
administration route, several studies have shown that the intra-
muscular administration of a vaccine stimulates a different immune
response from that stimulated by administration of antigens orally
[37e39]. In ﬁsh, as in higher vertebrates, there is a very complex
mucosa associated lymphoid tissue (MALT) in the gut (GALT), skin
(SALT), nasopharynx (NALT) and gills (GIALT), with a speciﬁc and
specialized immune response for these tissues [14,39,40]. In the
ﬁsh intestine, for instance, CD8þ T cells dominate the CD4þ subset
and the number of such cells increases from the foregut to the
hindgut [41]. Oral and anal administration in ﬁsh activates GALT,
while injection generally does not activate this stimulatory route
[14]. Although we did not study local GALT immune responses,
which might be very important after oral vaccination, CD4 (a
classical marker of T helper cells) and CD8 (a marker of cytotoxic
lymphocytes) transcripts were measured in response to the oral or
intramuscular administration of pIRF1A-G vaccine in internal or-
gans of the vaccinated ﬁsh at 15 days p. v. Our results showed
higher CD4 and CD8 expression levels in kidney of ﬁsh vaccinated
with 100 mg of the oral vaccine than in the i.m. injected ﬁsh.
Intramuscularly injected ﬁsh did not show a signiﬁcant increase in
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stimulate different cellular immune responses.
Until recently, teleost ﬁsh B cells were thought to express only
two classes of immunoglobulins, IgM and IgD, in which IgM was
thought to be the only Ig responding to pathogens both in systemic
and mucosal compartments. However, a third teleost immuno-
globulin class IgT, similar to zebraﬁsh IgZ, appears to play an
essential role in gut mucosal immune responses [34]. Previously,
we analysed local production of Igs in one of the ﬁsh intestinal
segments where mucosal immunity is induced after oral vaccina-
tion, the pyloric caeca [42]. Increased IgM and IgT expression levels
in pyloric ceca compared to kidney were detected after the oral
administration of alginate microparticles containing pcDNA-VP2
DNA vaccine [17]. In our current study, we measured IgM and IgT
production in head kidney and spleen after the oral or intramus-
cular administration of pIRF1A-G. In teleost ﬁsh, the head kidney is
considered the primary lymphoid tissue, a key hematopoietic or-
gan, and an important source of Ig-secreting B cells [14]. The spleen,
like the head kidney, also contains a large number of B cells and is
an organ inwhich activation and differentiation of B cells occur. Our
results showed differential modulation of IgM and IgT 15 days after
the oral or intramuscular delivery of pIRF1A-G. While the oral
administration of 100 mg of pIRF1A-G vaccine resulted in a signiﬁ-
cant induction of both IgM and IgT gene expression in kidney and
spleen of the vaccinated ﬁsh, the intramuscular delivery of the
vaccine only induced signiﬁcant levels of IgT expression in spleen of
vaccinated ﬁsh. No signiﬁcant production of IgT was detected in
kidney of the i. m. injected ﬁsh, conﬁrming IgT up regulation only
when the vaccinewas orally administered. In agreement with these
results, no signiﬁcant differences in IgM production were detected
in serum samples from intramuscular and oral vaccinated ﬁsh at
the three assessed p. v. time points. It should be pointed out that
the efﬁcient induction of a local immune response in the GALT after
oral vaccination was shown to induce a more intense immune
response than the systemic immunization [14,43]. Therefore, the
detection of antibodies in the gut mucus after the administration of
oral DNA vaccines should be a matter of further evaluation. In
addition, further research is needed to understand the role of the
mucosa-associated IgT in the teleosts's gut.
The effect of ﬁve doses of the oral pIRF1A-G vaccine on ﬁsh CPM
was evaluated. Fish injected with 5 mg of pIRF1A-G were used as a
positive control group. Dose response was evident for the oral
pIRF1A-G treatment groups. Statistically signiﬁcant differences in
mortalities between the ﬁsh orally vaccinated with 10, 20, 25 and
50 mg of the oral DNA vaccine and the empty-plasmid vaccinated or
unvaccinated ﬁsh were observed. The oral administration of 100 mg
of pIRF1A-G encapsulated in alginate microparticles to rainbow
trout protected against the infection, reaching an RPS value of 56,
which is less than the RPS obtained when 5 mg of pIRF1A-G vaccine
were i. m. injected (RPS ¼ 70). However, in a previous study, the i.
m. administration of 5 mg of pIRF1A-G resulted in protection levels
up to 55 RPS [8]. RPS differences between both studies might be
explained by differences in mortalities in the control treatment
groups. Other authors previously assayed oral DNA vaccines against
IHNV encapsulated by the polymer poly-(D,L-lactic-coglycolic acid)
(PLGA) and added to feed [44]. The induced protection was much
lower than that achieved with the intramuscularly injected vaccine
and was also lower than that described here for the alginate-
encapsulated pIRF1A-G vaccine. However, both alginate and PLGA
carrier systems provide accurate plasmid coating, as persistence of
transgene expression was observed in several tissues after
vaccination.
In summary, our results demonstrated that alginate micro-
spheres protected the pIRF1A-G vaccine which was expressed in
several organs of vaccinated trout. A low dose of the oral vaccine(10 mg) was able to stimulate the expression of IFN-1, TLR-7 and IgM
gene in kidney of orally vaccinated ﬁsh. In addition, the oral
administration of 10 mg of pIRF1A-G vaccine resulted in a signiﬁcant
induction of Mx-1, Vig-1, Vig-2 and TLR-3 gene expression at
3 d p. v. in spleen of vaccinated trout. In contrast, signiﬁcant Mx-3
and TLR-8 gene expression was only detected when high doses of
pIRF1A-G vaccine were orally administered. High doses of the oral
DNA vaccine (50 and 100 mg) induced anti-IHNV antibodies and
protected 45 and 56% of the vaccinated trout, respectively. How-
ever, there is still need for improvement of this oral IHNV vaccine.
An approach to reduce the amount of pIRF1A-G required for oral
vaccination and to increase its immunogenicity might be the co-
administration of encapsulated mucosal adjuvants such as tradi-
tional aluminium salts, polysaccharides (e. g. zymosan, glucans,
chitosan), and TLR agonists [5,45]. Moreover, the oral administra-
tion of plasmids encoding cytokine adjuvants (IL-8, IL-2, IFN-g, IL-
12, GM-CSF and IL-15) may be another approach to increase the
immunogenicity of the oral pIRF1A-G vaccine [45,46]. As CD8þ cells
dominate the CD4þ subset in the intestine, oral DNA vaccines
should be developed to speciﬁcally target these effectors immune
cells at the mucosal surfaces as a way to increase their efﬁcacy.
Induction of long-term memory by speciﬁc stimulation of mucosa-
associated IgT should also be considered. Perhaps such improve-
ments could also increase the efﬁcacy of the oral pIRF1A-G vaccine
in terms of survival (>56 RPS). In other hand, it remains to be
determined whether the addition of the oral pIRF1A-G vaccine to
food pellets could serve as an efﬁcient method of inducing pro-
tective immune responses against IHNV infection. Using this
approach, the plasmid could be easily delivered in multiple suc-
cessive events, avoiding ﬁsh stress and likely increasing vaccine
effectiveness. Previously, we demonstrated that oral vaccine de-
livery through feeding is a promising delivery method, at least for
IPNV vaccines [19]. In conclusion, our results demonstrated a sig-
niﬁcant increase in ﬁsh immune responses and resistance to an
IHNV infection after the oral administration of increasing concen-
trations of a DNA vaccine against IHNV encapsulated into alginate
microspheres.
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